Safety and efficacy of peptide receptor radionuclide therapy in treating high-risk patients with extensive neuroendocrine tumors

#3201

Introduction: Neuroendocrine tumors (NETs) are a rare group of neoplasms. Peptide receptor radionuclide therapy (PRRT) is a well-recognized treatment modality for NETs that express somatostatin receptors (SSRs) on neuroendocrine cells’ surface. While many studies assessed the efficacy and safety in all NET patients, only a few focused on high-risk patients.

Aim(s): This study aims to evaluate the efficacy and safety of PRRT in high-risk patients including patients with extensive liver metastases, extensive skeletal metastases, extensive tumor burden.

Materials and methods: A retrospective analysis of 394 patients with metastatic progressive NETs who were treated with 4 cycles of 7.4GBq of 177Lu-DOTATATE. We evaluated patients with high volume disease: extensive liver metastases (>50%) (n= 86), extensive skeletal metastases (>50% involvement of the skeleton) (n=44), extensive tumor burden (n=45). We evaluated the outcome and toxicity data.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Alsadik S, Gnanasegaran G, Chen L, Toumpanakis C, Caplin M,

Keywords: neuroendocrine tumor, NET, peptide receptor radionuclide therapy PRRT, 177lu-DOTATATE, extensive liver metastases, extensive skeletal metastases, extensive tumor burden,